Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Avinash Mesipam

Diagnostic Radiology Saint Louis, MO Medical Doctor

NPI 1427495316 CMS profile 4222267

1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110

Open in the dashboard

General payments

$22,748

267 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Avinash Mesipam of Saint Louis, MO is reported in the CMS Open Payments database as having received $22,748 across 267 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,910 55
2024 General $5,122 43
2023 General $4,033 63
2022 General $1,949 38
2021 General $2,202 45
2020 General $2,104 11
2019 General $1,429 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Avinash Mesipam
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Avinash Mesipam were reported at $5,910. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Avinash Mesipam Diagnostic Radiology median Middle half National median
2019 $1,429 $108 $29–$318 $163
2020 $2,104 $65 $21–$252 $114
2021 $2,202 $92 $24–$292 $132
2022 $1,949 $104 $29–$294 $149
2023 $4,033 $110 $29–$337 $160
2024 $5,122 $113 $30–$356 $164
2025 $5,910 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,559 96 payments
  2. Penumbra, Inc. $4,107 25 payments
  3. Stryker Corporation $2,747 36 payments
  4. Medtronic USA, Inc. $2,403 15 payments
  5. Balt USA, LLC $1,420 6 payments
  6. DePuy Synthes Sales Inc. $1,198 20 payments
  7. MicroVention, Inc. $1,009 10 payments
  8. Inari Medical, Inc. $643 6 payments
  9. Terumo Medical Corporation $514 6 payments
  10. Scientia Vascular $365 1 payment
  11. Other $1,783 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,754 248 payments
  2. Travel and Lodging $4,106 16 payments
  3. Consulting Fee $2,538 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $350 1 payment
Products named General payments · program years 2019–2025
  1. Penumbra System $3,087 16 payments
  2. Pipeline $1,750 21 payments
  3. Carrier Delivery Catheter $1,173 4 payments
  4. TARGET $978 9 payments
  5. KYPHON Balloon Kyphoplasty $879 19 payments
  6. CT THROMBECTOMY SYSTEM KIT $774 10 payments
  7. FLOWTRIEVER CATHETER, S $774 10 payments
  8. Indigo System $668 5 payments
  9. Solitaire $660 8 payments
  10. TRUFILL $562 9 payments
  11. Other $12,668 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

29

Median for Diagnostic Radiology: 24

Drug cost

$6,292

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 15 $6,219
Clopidogrel Clopidogrel Bisulfate Brand 14 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 168 billing codes

Paid by Medicare

$136,611

Medicare's payments for the services billed

Medicare patients

745

Average age 77

Services billed

1,662

375 women, 370 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 39%
Chronic kidney disease 38%
Diabetes 34%
Cancer 34%
Atrial fibrillation 33%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record